| | | | | 1 | | | |
| | | | | 1 | | | |
| | | | | 9 | | | |
| | | | | 16 | | | |
| | | | | 18 | | | |
| | | | | 24 | | | |
| | | | | 41 | | | |
| | | | | 60 | | | |
| | | | | 64 | | | |
| | | | | 66 | | | |
| | | | | 68 | | | |
| | | | | 70 | | | |
| | | | | 71 | | | |
| | | | | 71 | | | |
| | | | | A-1 | | | |
| | | | | B-1 | | | |
| | | | | C-1 | | |
(in millions, except for share and per share amounts)
|
| |
Low
|
| |
High
|
| ||||||
Cash and cash equivalents as of March 31, 2024
|
| | | $ | 3.49 | | | | | $ | 3.49 | | |
Purchase price from Immunome
|
| | | $ | 5.50 | | | | | $ | 5.50 | | |
Estimated Proceeds, Expenses and Cash Reserves | | | | | | | | | | | | | |
Operating expenses after March 31, 2024(1)
|
| | | $ | (0.74) | | | | | $ | (0.64) | | |
Assumed severance for executive officers(2)
|
| | | $ | (1.41) | | | | | $ | (1.41) | | |
Assumed severance for other employees(3)
|
| | | $ | (0.24) | | | | | $ | (0.24) | | |
Accounts payable and accrued liabilities(4)
|
| | | $ | (1.24) | | | | | $ | (1.01) | | |
Insurance(5) | | | | $ | (1.37) | | | | | $ | (1.37) | | |
Professional fees (attorneys, accountants, consultants)(6)
|
| | | $ | (0.30) | | | | | $ | (0.30) | | |
Reserve for potential or unanticipated claims and contingencies
|
| | | $ | (1.00) | | | | | $ | (1.00) | | |
Reserve for MAM01/ATRC-501 post asset sale close
|
| | | $ | (0.40) | | | | | $ | (0.40) | | |
Reserve for remaining asset intellectual property prosecution and maintenance
|
| | | $ | (0.22) | | | | | $ | (0.22) | | |
Total
|
| | | $ | (6.93) | | | | | $ | (6.60) | | |
Estimated cash to distribute to stockholders
|
| | | $ | 2.06 | | | | | $ | 2.39 | | |
Assumed shares outstanding(7)
|
| | | | 39,653,242 | | | | | | 39,653,242 | | |
Estimated initial liquidating distribution per share
|
| | | $ | 0.05 | | | | | $ | 0.06 | | |
Name
|
| |
Cash
Severance Payment |
| |
COBRA
Benefits |
| |
Accelerated
Vesting of Equity Awards |
| |
Aggregate
Severance Benefits |
| ||||||||||||
John A. Orwin
|
| | | $ | 625,039 | | | | | $ | 42,912 | | | | | | — | | | | | $ | 667,951 | | |
Courtney J. Phillips
|
| | | $ | 337,500 | | | | | | — | | | | | | — | | | | | $ | 337,500 | | |
Tito A. Serafini, Ph.D.(1)
|
| | | $ | 377,961 | | | | | $ | 32,181 | | | | | $ | 1,458(2) | | | | | $ | 411,600 | | |
Stephen E. Gould, Ph.D.(3)
|
| | | $ | 356,250 | | | | | $ | 32,181 | | | | | | — | | | | | $ | 388,431 | | |
Philippe M. Bishop, M.D.(4)
|
| | | $ | 356,250 | | | | | $ | 10,323 | | | | | | — | | | | | $ | 366,573 | | |
Name
|
| |
Cash
Severance Payment |
| |
Bonus
Payment |
| |
COBRA
Benefits |
| |
Aggregate
Deferred and Contingent Severance Benefits |
| ||||||||||||
John A. Orwin
|
| | | $ | 312,520 | | | | | $ | 515,657(1) | | | | | $ | 21,456 | | | | | $ | 849,633 | | |
Tito A. Serafini, Ph.D.
|
| | | $ | 125,987 | | | | | $ | 201,579(2) | | | | | $ | 10,728 | | | | | $ | 338,294 | | |
Courtney J. Phillips
|
| | | $ | 112,500 | | | | | $ | 180,000(3) | | | | | $ | 1,083 | | | | | $ | 293,583 | | |
Name
|
| |
Number of Shares of
Class A Common Stock Owned(1) |
| |||
John A. Orwin(2)
|
| | | | 77,541 | | |
Courtney J. Phillips
|
| | | | 28,764 | | |
Brian Atwood
|
| | | | 49,654 | | |
Kristine M. Ball
|
| | | | — | | |
Franklin Berger
|
| | | | 97,808 | | |
David Lacey, M.D.
|
| | | | — | | |
William H. Robinson, M.D., Ph. D.
|
| | | | 368,948 | | |
Stacey Ma, Ph.D.
|
| | | | — | | |
Stephen Brady
|
| | | | — | | |
Lindsey Rolfe, M.D.
|
| | | | — | | |
Tito A. Serafini, Ph.D.
|
| | | | 322,511 | | |
| | |
Shares Beneficially Owned
|
| |||||||||||||||||||||
Beneficial Owner
|
| |
Number of
shares of Class A common stock |
| |
Percentage of
shares of Class A common stock |
| |
Number of
shares of Series A Junior Preferred Stock |
| |
Percentage of
shares of Series A Junior Preferred Stock |
| ||||||||||||
Greater than 5% Stockholders | | | | | | | | | | | | | | | | ||||||||||
Entities Affiliated with Baker Brothers Life Sciences, L.P.(1)
|
| | | | 7,677,982(2) | | | | | | 19.9% | | | | | | — | | | | | | — | | |
Entities Affiliated with Boxer Capital, LLC(3)
|
| | | | 2,202,333 | | | | | | 5.7% | | | | | | — | | | | | | — | | |
Directors and Named Executive Officers
|
| | | | | | | | | | | | | | | | | | | | | | | | |
John A. Orwin(4)
|
| | | | 77,541 | | | | | | * | | | | | | 1 | | | | | | 100% | | |
Tito A. Serafini, Ph.D.(5)
|
| | | | 322,511 | | | | | | * | | | | | | — | | | | | | — | | |
Brian Atwood(6)
|
| | | | 49,654 | | | | | | * | | | | | | — | | | | | | — | | |
Kristine M. Ball
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Franklin Berger(7)
|
| | | | 97,808 | | | | | | * | | | | | | — | | | | | | — | | |
Stephen R. Brady
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
David Lacey, M.D.
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Stacey Y. Ma, Ph.D.
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
William Robinson, M.D., Ph.D.(8)
|
| | | | 368,948 | | | | | | * | | | | | | — | | | | | | — | | |
Lindsey Rolfe, MBChB
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Stephen E. Gould(9)
|
| | | | 6,757 | | | | | | * | | | | | | — | | | | | | — | | |
All executive officers and directors as a group (11 persons)(10)
|
| | | | 945,226 | | | | | | 2.5% | | | | | | 1 | | | | | | 100% | | |
| | |
Page
|
| |||
| | | | A-1 | | | |
| | | | A-1 | | | |
| | | | A-9 | | | |
| | | | A-9 | | | |
| | | | A-9 | | | |
| | | | A-11 | | | |
| | | | A-11 | | | |
| | | | A-11 | | | |
| | | | A-12 | | | |
| | | | A-12 | | | |
| | | | A-12 | | | |
| | | | A-18 | | | |
| | | | A-19 | | | |
| | | | A-19 | | | |
| | | | A-20 | | | |
| | | | A-20 | | | |
| | | | A-20 | | | |
| | | | A-20 | | | |
| | | | A-21 | | | |
| | | | A-21 | | | |
| | | | A-21 | | | |
| | | | A-21 | | | |
| | | | A-21 | | | |
| | | | A-21 | | | |
| | | | A-21 | | | |
| | | | A-22 | | | |
| | | | A-23 | | | |
| | | | A-23 | | | |
| | | | A-23 | | | |
| | | | A-27 | | | |
| | | | A-27 | | | |
| | | | A-28 | | | |
| | | | A-28 | | | |
| | | | A-29 | | | |
| | | | A-29 | | | |
| | | | A-29 | | | |
| | | | A-30 | | | |
| | | | A-30 | | | |
| | | | A-30 | | | |
| | | | A-30 | | | |
| | | | A-30 | | |
| | |
Page
|
| |||
| | | | A-30 | | | |
| | | | A-31 | | | |
| | | | A-31 | | | |
| | | | A-31 | | | |
| | | | A-31 | | | |
| | | | A-32 | | | |
| | | | A-32 | | | |
| | | | A-32 | | | |
| | | | A-32 | | | |
| | | | A-32 | | | |
| | | | A-33 | | | |
| | | | A-33 | | | |
| | | | A-34 | | | |
| | | | A-34 | | | |
| | | | A-34 | | | |
| | | | A-34 | | | |
| | | | A-34 | | | |
| | | | A-34 | | | |
| | | | A-34 | | | |
| | | | A-34 | | | |
| | | | A-35 | | |
| SCHEDULES | | | | |
|
Schedule 2.1.2(a)
Assumed Contracts
|
| | | |
|
Schedule 2.1.2(b)
Seller IP
|
| | | |
|
Schedule 2.1.2(e)
Regulatory Approvals
|
| | | |
|
Schedule 2.1.2(f)
Specified Samples
|
| | | |
|
Schedule 2.1.4
Assumed Liabilities
|
| | | |
|
Schedule 6.8
Stockholders Meeting
|
| | | |
| EXHIBITS | | | | |
|
Exhibit A
Form of Assignment and Bill of Sale
|
| | | |
|
Exhibit B
Form of Patent Assignment
|
| | | |
| | | | | |
| | | | |
| | | | ATRECA, INC. | |
| | | |
By:
/s/ John A. Orwin
Name: John A. Orwin
Title: President and Chief Executive Officer |
|
| | | | IMMUNOME, INC. | |
| | | |
By:
/s/ Clay Siegall
Name: Clay Siegall
Title: President and Chief Executive Officer |
|
| | | | COMPANY | |
| | | | Atreca, Inc. | |
| | | |
Name:
Title: |
|
| | | | PURCHASER | |
| | | | Immunome, Inc. | |
| | | |
Name:
Title: |
|
| | | | STOCKHOLDER | |
| | | | [NAME] | |
| | | |
|
|
| | | | Email: [ ] | |
| |
Name
|
| | |
Class A
Common Stock |
| | |
Class B
Common Stock |
| | |
Company Options
|
| | |
Restricted Stock
Units |
| |
| | | | | | | | | | | | | | | | | | | | |
| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 1 | | | |
| | | | 3 | | | |
| | | | 3 | | | |
| | | | 3 | | | |
| | | | 3 | | | |
| | | | 4 | | | |
| | | | 5 | | | |
| | | | 5 | | | |
| | | | 6 | | | |
| | | | 6 | | | |
| | | | 6 | | | |
| | | | 8 | | | |
| | | | 9 | | | |
| | | | 9 | | | |
| | | | 9 | | | |
| | | | 9 | | | |
| | | | 9 | | | |
| | | | 9 | | | |
| | | | 9 | | | |
| | | | 10 | | | |
| | | | 10 | | | |
| | | | 10 | | | |
| | | | 10 | | | |
| | | | 11 | | | |
| | | | 11 | | | |
| | | | 11 | | | |
| | | | 11 | | | |
| | | | 12 | | | |
| | | | 12 | | | |
| | | | 12 | | | |
| | | | 12 | | | |
| | | | 12 | | | |
| | | | 12 | | | |
| | | | 13 | | | |
| | | | 13 | | | |
| | | | 13 | | |
| | | | Immunome, Inc. | |
| | | |
|
|
| | | | [ ], as Rights Agent | |
| | | |
|
|